SPAG9 is altered in 0.04% of all cancers with gastric adenocarcinoma, glioblastoma, invasive breast carcinoma, acute myeloid leukemia, and anal squamous cell carcinoma having the greatest prevalence of alterations .
The most common alterations in SPAG9 are SPAG9-JAK2 Fusion (0.10%) and SPAG9-RAD51D Fusion (0.00%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.